When CRAF knockdown or MEK inhibition—mediated by CRAF siRNAs or MEK blockade—was combined with sorafenib, we found reduced ERK activation, increased Bim and apoptosis induction and thus decreased HCC cell viability. The gene discussed is RAF1; the disease is hepatocellular carcinoma.